HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO Qyuns Therapeutics (PHIP Updates) - Some Points Worth the Attention

Pre-IPO Cloudbreak Pharma - The Business, the Concerns and the Outlook

China Healthcare Weekly (Feb.23)- TCM Ushers in a Harvest Period, Biotech Bottom-Line, Kelun-Biotech

Ping An Healthcare and Technology (1833.HK) - Valuation Logic May Completely Change Due to New Path

Escalation of Israel-Hamas War - Here's How Investors Should Position Themselves in Dramatic Changes

Wuxi Biologics (2269.HK) - The Latest Updates Related to 2024 Performance Worth the Attention

Equity Capital Markets

<ul>
<li>PB-119 (T2DM) has the fastest R&amp;D progress, but this is a highly competitive market.China's diabetes drug market is dominated by traditional drugs. It’s not easy for PegBio to break through. </li>
<li>Since the future competitive landscape of GLP-1s (obesity) would present a very different situation.If PB-119 fails to have better weight loss effect, it would be eliminated due to fierce competition.</li>
<li>PegBio’s IPO on SSE STAR Market was rejected. We’re not optimistic about its future commercialization performance. Together with cash-flow issues, we doubt whether PegBio would bring expected returns to investors.</li>
</ul>


PB-119 (T2DM) has the fastest R&amp;D progress, but this is a highly competitive market.China's diabetes drug market is dominated by traditional drugs. It’s not easy for PegBio to break through. 
Since the future competitive landscape of GLP-1s (obesity) would present a very different situation.If PB-119 fails to have better weight loss effect, it would be eliminated due to fierce competition.
PegBio’s IPO on SSE STAR Market was rejected. We’re not optimistic about its future commercialization performance. Together with cash-flow issues, we doubt whether PegBio would bring expected returns to investors.


Pre-IPO PegBio Co., Ltd. - This GLP-1 Biotech Has Gloomy Outlook